You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Relvar Ellipta 92/22mcg and 185/92mcg pack shot

Product overview

Relvar Ellipta is an ICS/LABA combination for the treatment of asthma and COPD [1] [2]. Relvar is the only ICS/LABA which is one inhalation, once daily which delivers 24 hours of continuous efficacy. For information about the differing licensed doses in asthma and COPD, please see Indications page.

*SMC= Scottish Medicines Consortium

ǂ AWMSG= All Wales Medicines Strategy Group

Innoviva logo

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Relvar, Incruse and Ellipta are registered trademarks of the GlaxoSmithKline group of companies